We serve Chemical Name:4-Cyclopropyl-1,3-thiazole-2-carboxylic Acid CAS:1083274-67-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-Cyclopropyl-1,3-thiazole-2-carboxylic Acid
CAS.NO:1083274-67-2
Synonyms:4-Cyclopropylthiazole-2-carboxylic acid
Molecular Formula:C7H7NO2S
Molecular Weight:169.20100
HS Code:2934100090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:78.43000
Exact Mass:169.02000
LogP:1.71870
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-Cyclopropylthiazole-2-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Cyclopropylthiazole-2-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Cyclopropylthiazole-2-carboxylic acid Use and application,4-Cyclopropylthiazole-2-carboxylic acid technical grade,usp/ep/jp grade.
Related News: With the chemical industry being one of the most polluting, global efforts are heavily focused on developing a more sustainable and greener footprint. 4-chloro-N-propylpyridine-2-carboxamide manufacturers Zynteglo was granted conditional marketing authorisation in May 2019. The conditional authorisation means that there is more evidence to come about the medicine, which the company will provide. EMA regularly reviews new information that becomes available. 2-chloro-4-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine suppliers Only four out of the eight studies showed a reduction in ‘off’ time, and the effect did not increase with an increased dose of Nouryant.” 2-Bromo-5-iodobenzaldehyde vendor & factory Though the program obtained priority review from FDA back in November, analysts expressed skepticism in July 2020 after it failed to prove superior to the companies’ other drug Lumizyme in improving respiratory function in a Phase III trial.,AstraZeneca’s deal, the largest struck last year, is all part of CEO Pascal Soriot’s mission to hit $40 billion in global sales by 2023.
